James A Radosevich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9399577/publications.pdf

Version: 2024-02-01

10
g-index
157
ked citing authors

#	Article	IF	CITATIONS
1	Charge Dependence of Cellular Uptake and Selective Antitumor Activity of Porphyrazines. Journal of Medicinal Chemistry, 2005, 48, 8125-8133.	6.4	32
2	Developing a structure–function relationship for anionic porphyrazines exhibiting selective anti-tumor activity. Journal of Photochemistry and Photobiology B: Biology, 2006, 82, 180-186.	3.8	26
3	Chiral <i>bis</i> à€Acetal Porphyrazines as Nearâ€infrared Optical Agents for Detection and Treatment of Cancer. Photochemistry and Photobiology, 2010, 86, 410-417.	2.5	22
4	Synthesis and Biological Analysis of Thiotetra(ethylene glycol) monomethyl Ether-Functionalized Porphyrazines: Cellular Uptake and Toxicity Studies. Metal-Based Drugs, 2008, 2008, 1-13.	3.8	13
5	Dual Role of microRNAs in Autophagy of Colorectal Cancer. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 56-66.	1.2	7
6	Monoclonal Antibody 44–3A6 as a Marker for Breast Carcinoma. Tumor Biology, 1991, 12, 254-260.	1.8	6
7	Monoclonal antibody 44-3A6 as an adjunct in cytodiagnosis of adenocarcinomas in body fluids. Diagnostic Cytopathology, 1993, 9, 179-183.	1.0	6
8	DNA Methylation in Human Breast Cancer Cell Lines Adapted to High Nitric Oxide. In Vivo, 2020, 34, 169-176.	1.3	4
9	Labyrinthin: A distinct pan-adenocarcinoma diagnostic and immunotherapeutic tumor specific antigen. Heliyon, 2022, 8, e08988.	3.2	4
10	<p>Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer</p> . OncoTargets and Therapy, 2019, Volume 12, 9351-9354.	2.0	3